Infectious Agents and Cancer 2013-01-01

c-Met inhibitors.

Anum Mughal, Hafiz Muhammad Aslam, Asfandyar Sheikh, Agha Muhammad Hammad Khan, Shafaq Saleem

Index: Infect. Agents Cancer 8(1) , 13, (2013)

Full Text: HTML

Abstract

c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy.

Related Compounds

  • SU11274

Related Articles:

Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells.

2015-01-01

[Cancer Biol. Ther. 16(1) , 170-5, (2015)]

Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.

2013-01-01

[PLoS ONE 8(3) , e59708, (2013)]

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

2005-02-15

[Cancer Res. 65 , 1479-1488, (2005)]

More Articles...